A Phase 3 interventional study of terbinafine and Placebo in Onychomycosis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 3 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.
Among the 20 studies testing terbinafine in Onychomycosis, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2006, is one of 10 in phase 3, and was the 1st registered.
158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.
Browse Onychomycosis studies →1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:
Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →
Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 526 is above the median of 60 across 143 interventional studies indexed under Onychomycosis.
Median enrollment 100 across the 19 interventional studies. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Onychomycosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing terbinafine in Onychomycosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
Drug: terbinafine
Vehicle (placebo) for 48 weeks
Drug: Placebo
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
Drug: terbinafine
Vehicle (placebo) for 24 weeks
Drug: Placebo
Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
Also known as: Lamisil
Vehicle (placebo) once daily for 48 weeks
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
Also known as: Lamisil
Vehicle (placebo) once daily for 24 weeks
Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks
Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
Time frame: 52 weeks
Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks
Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.
Time frame: 52 weeks
Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if: * If mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise
Time frame: 52 weeks
Safety and Tolerability Assessed by the Number of Participants With Adverse Events
Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.
Time frame: 52 weeks
This randomized, double -blind, vehicle -controlled, multicenter, parallel group study was designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine hydrogen chloride 10% topical solution (TTS10%) applied daily in patients with toenail onychomycosis. Started 07 DEC 2006 and ending 27 JUN 2008.
| Milestone | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks |
|---|---|---|---|---|
| Started | 133 | 130 | 135 | 128 |
| Safety population | 131 | 129 | 134 | 126 |
| Completed | 112 | 111 | 117 | 111 |
| Not completed | 21 | 19 | 18 | 17 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 2 | 1 | 1 |
| Withdrew: Protocol violation | 2 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 6 | 7 | 8 | 9 |
| Withdrew: Lost to follow-up | 9 | 8 | 6 | 5 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
| Percentage of participants | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks |
|---|---|---|---|---|
| Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks | 1.50 (-1.82 to 3.29) | 0.77 (-1.82 to 3.29) | 2.96 (0.10 to 5.82) | 0 (0.10 to 5.82) |
Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.
| Percentage of participants | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks |
|---|---|---|---|---|
| Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks | 15.04 (1.54 to 16.23) | 6.15 (1.54 to 16.23) | 22.22 (6.00 to 22.82) | 7.81 (6.00 to 22.82) |
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if: * If mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise
| Percentage of participants | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks |
|---|---|---|---|---|
| Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks | 3.01 | 0.77 | 5.93 | 0.78 |
Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.
| Number of participants | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks |
|---|---|---|---|---|
| At least 1 AE | 80 | 72 | 94 | 87 |
| At least 1 SAE | 8 | 3 | 9 | 7 |
| Study drug discontinued due to an AE | 0 | 1 | 1 | 0 |
| Death | 0 | 0 | 1 | 0 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Terbinafine 24 Weeks | — | 8/131 (6.1%) | 37/131 (28.2%) |
| Vehicle 24 Weeks | — | 3/129 (2.3%) | 38/129 (29.5%) |
| Terbinafine 48 Weeks | — | 9/134 (6.7%) | 54/134 (40.3%) |
| Vehicle 48 Weeks | — | 7/126 (5.6%) | 52/126 (41.3%) |
| Event | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks |
|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/131 | 0/129 | 0/134 | 0/126 |
| TachycardiaCardiac disorders | 0/131 | 0/129 | 0/134 | 1/126 |
| ConstipationGastrointestinal disorders | 0/131 | 0/129 | 0/134 | 1/126 |
| PneumoniaInfections and infestations | 0/131 | 0/129 | 0/134 | 1/126 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/131 | 0/129 | 0/134 | 1/126 |
| Back painMusculoskeletal and connective tissue disorders | 0/131 | 0/129 | 1/134 | 1/126 |
| Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/131 | 0/129 | 0/134 | 1/126 |
| SciaticaNervous system disorders | 0/131 | 0/129 | 0/134 | 1/126 |
| Bladder prolapseRenal and urinary disorders | 0/131 | 0/129 | 0/134 | 1/126 |
| DysuriaRenal and urinary disorders | 0/131 | 0/129 | 0/134 | 1/126 |
| Event | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks |
|---|---|---|---|---|
| HeadacheNervous system disorders | 21/131 | 21/129 | 28/134 | 23/126 |
| NasopharyngitisInfections and infestations | 13/131 | 11/129 | 15/134 | 15/126 |
| InfluenzaInfections and infestations | 2/131 | 1/129 | 13/134 | 10/126 |
| Back painMusculoskeletal and connective tissue disorders | 8/131 | 7/129 | 6/134 | 12/126 |
| Upper respiratory tract infectionInfections and infestations | 4/131 | 4/129 | 4/134 | 10/126 |
| HypertensionVascular disorders | 1/131 | 3/129 | 8/134 | 4/126 |
| SinusitisInfections and infestations | 3/131 | 0/129 | 4/134 | 7/126 |
| Age, Categorical(Participants) | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 1 | 1 |
| Between 18 and 65 years | 93 | 103 | 95 | 97 | 388 |
| >=65 years | 40 | 27 | 40 | 30 | 137 |
| Sex: Female, Male(Participants) | Terbinafine 24 Weeks | Vehicle 24 Weeks | Terbinafine 48 Weeks | Vehicle 48 Weeks | Total |
|---|---|---|---|---|---|
| Female | 34 | 39 | 41 | 35 | 149 |
| Male | 99 | 91 | 94 | 93 | 377 |
The record gives a start of Dec 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Terbinafine